| Objective: | US post-approval safety surveillance study |
| Number of Patients: | 5,000 |
| Number of Sites: | Up to 60 |
| Lesion Type: | All inclusive and open registry of consecutive patients |
| Stent Platform: | TAXUS® Express2™ Paclitaxel-Eluting Stent |
| Release Kinetics: | Slow |
| Primary Endpoint: | 1-year site reported cardiac events |
| P.I. and Co-P.I.: | D. Cox, MD and J. Lasala, MD, PhD |
| Status: | Enrollment Complete |
